Compare OVLY & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | CERS |
|---|---|---|
| Founded | 1990 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 276.0M |
| IPO Year | 2008 | 1996 |
| Metric | OVLY | CERS |
|---|---|---|
| Price | $34.71 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 1.4M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ 2.88 | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | $12.06 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $23.27 | $1.15 |
| 52 Week High | $34.80 | $2.96 |
| Indicator | OVLY | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 71.84 | 56.71 |
| Support Level | $29.45 | $1.93 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.59 | 0.09 |
| MACD | 0.29 | 0.04 |
| Stochastic Oscillator | 97.30 | 87.69 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.